Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Avastin + Docetaxel as First-Line Therapy for Metastatic Breast Cancer
2008-003527-24Phase 2Completed
- Sponsor
- Tampere University Hospital
- Start
- Oct 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and docetaxel in breast cancer and breast adenocarcinoma, sponsored by Tampere University Hospital. Primary endpoint: Progression-free survival. Started Oct 2008; status: completed.
02
Drugs
bevacizumabdocetaxel
03
Conditions
breast cancerbreast adenocarcinoma
Beyond the preview
Go deeper on 2008-003527-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003527-24.